SCHEMBL6733353

SCHEMBL6733353

O=C(O)c1ccc(COc2cc(-c3ccc(N4C(=O)c5ccc(C(=O)O)cc5C4=O)cc3)nc(-c3ccccc3)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.62
PPARA Q07869 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
GFER P55789 1/20 0.48
KDM4E B2RXH2 1/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA9 Q16790 3/20 0.46
CA2 P00918 2/20 0.46
SCN2A Q99250 1/20 0.46
HPSE Q9Y251 5/20 0.46
CA4 P22748 2/20 0.46
CA7 P43166 1/20 0.46
ALDH1A1 P00352 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6727777 0.93 POLB (0.56) POLBPPARAMEN1KMT2AGFER
SCHEMBL4804158 0.84 RXRA (0.53) MEN1KMT2A
SCHEMBL4802532 0.80 CTRC (0.55) POLBMEN1KMT2AKDM4EMAPT
SCHEMBL4807278 0.78 RXRA (0.48) KDM4E
SCHEMBL6738994 0.75 MEN1 (0.69) POLBMEN1KMT2AGFERKDM4E
SCHEMBL7838700 0.75 POLB (0.55) POLBMEN1KMT2AGFERKDM4E
SCHEMBL8987052 0.73 LTB4R (0.59)
SCHEMBL13909220 0.73 CA9 (0.71) POLBPPARAMEN1KMT2AGFER
SCHEMBL4234750 0.73 CA9 (0.77) POLBPPARAMEN1KMT2AGFER
SCHEMBL9564296 0.72 CA9 (0.66) POLBPPARAMEN1KMT2AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis ARRHENIUS THOMAS (US) 2004-06-10 US disclosed
EP-1370250-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP disclosed
WO-2002076438-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis FLT1, FLT4, TEK POLB 1547/4885PPARA 583/4885MEN1 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.